Efficacy of clopidogrel in prevention of adverse cardiovascular events after interventional treatment in patients with coronary heart disease
Objective To investigate the clinical effect of prophylactic application of clopidogrel on cardiovascular adverse events in patients with coronary heart disease after interventional treatment.Methods A total of 112 patients recieving coronary intervention treatment in our hospital from April 2021 to April 2023 were enrolled in this study.These patients were randomized into the thiacloprid group and the clopidogrel group,with 56 in each.The patients in the ticlopidine group received prophylactic treatment with ticlopidine,and those in the clopidogrel group received prophylactic treatment with clopidogrel.The incidence of cardiovascular adverse events,clinical effects,changes in platelet aggregation rate and thrombin B2 index before and 24 h after treatment,and treatment satisfaction rate were compared bwteen the 2 groups.Results The incidence of cardiovascular adverse events(3.57%)was lower but the total effective rate(96.43%)higher in the clopidogrel group than in the ticlopidine group(14.29%)(86.71%)(χ2 = 3.952 9,P = 0.046 8;χ2 = 3.952 9,P = 0.046 8).There was no statistically significant difference in coagulation function indicators between 2 groups(P>0.05).There was no statistically remarkable difference in thromboxane B2 and platelet aggregation rate between two groups before treatment(P>0.05).Thromboxane B2 and platelet aggregation rate decreased in both groups after 24 h of treatment,and patients in the clopidogrel group had lower thromboxane B2[(42.38±6.23)pg·mL-1vs.(66.23±5.72)pg·mL-1]and platelet aggregation rate[(25.39±4.17)pg·mL-1vs.(30.26±3.76)pg·mL-1]as compared to the ticlopidine group after 24 h of treatment(t = 3.258 1,P = 0.025 3).The satisfaction rate of clopidogrel group(92.86%)was higher than that of ticlopidine group(78.57%)(χ2 = 4.666 7,P = 0.030 8).Conclusion The prophylactic application of clopidogrel after interventional therapyin patients with coronary heart disease can better prevent cardiovascular adverse events and improve the therapeutic effect.Therefore,most of the patients accept it.
Coronary heart diseaseInterventional therapyClopidogrelTiclopidineCardiovascular adverse eventCoagulation function
万方数据
维普
